Molecularly targeted therapy has enabled outstanding advances in cancer treatment.
Moreover, little is known about HER2 mutation in gastric cancer. 2, 3 Afatinib and neratinib are irreversible human EGFR TKIs that also bind to the kinase domains of HER2 and HER4. Both drugs are called pan-HER inhibitors. Afatinib has already been approved and clinically used as a treatment option for EGFR-mutant non-small-cell lung cancers, and it has also been reported to be effective against HER2-mutant or HER2-amplified non-small-cell lung cancers. 4, 5 Neratinib has been approved for the treatment of breast cancer by the US FDA, and an improvement in the overall survival of post-operative HER2-positive breast cancer patients after trastuzumab treatment has been reported. 6 Because these two drugs are promising candidates as anti-HER2 small molecular drugs for HER2-positive gastric cancer, we examined the antitumor effects of afatinib and neratinib against gastric cancer. We also analyzed HER2
alterations, including the mutation status, in primary gastric cancer from 123 Japanese patients who underwent a gastrectomy at our institution. 
| MATERIALS AND METHODS

| Cell lines and reagents
| Clinical tumor samples
Primary gastric cancer tumor samples were obtained from 123 patients who underwent a gastrectomy at Okayama University Hospital (Okayama, Japan). The median patient age was 68 years (range, 36-90 years), and all the patients were Japanese. Institutional
Review Board permission and informed consent were obtained at our institution.
| DNA and RNA extraction
The genomic DNA and RNA of 12 cell lines were extracted using 
| Western blot analysis and IHC
The detailed protocols of the total cell lysate extraction, Western blot analysis, and IHC have been described previously. 11, 12 The primary antibodies were as follows: p-HER2 (Tyr1221/1222), HER2, p-
(Cell Signaling Technology), and actin (Santa Cruz Biotechnology).
The following secondary antibodies were used in the Western blotting: anti-rabbit, anti-mouse (Santa Cruz Biotechnology). To detect specific proteins, the membranes were examined using the ECL Prime Western Blotting Detection System (GE Healthcare) and LAS-3000 (Fuji-film). As for IHC staining, the clinical tumors were stained using anti-HER2 primary antibody purchased from Roche Diagnostics.
| Cell growth inhibition assay
The cell growth inhibition rate was determined using a modified The sequences of the primers were the same as previously reported. 13, 14 The detailed PCR protocol has been previously reported, and all the PCR products were incubated using exonuclease I and shrimp alkaline phosphatase (Amersham Biosciences). DNA sequence alterations were evaluated using MutationTaster2. 
| Statistical analysis
In this study, the statistical analysis was mainly carried out using R, and numerical data were expressed as the mean AE SD. The difference between two groups was considered statistically significant at P < 0.05.
| Bioinformatics analysis
We used the microarray data (Affymetrix U133+2 arrays), genetic alterations, and drug sensitivities of the cell lines shown in the CCLE.
In the clinical bioinformatics analysis, we investigated the HER2 alterations listed in the TCGA, MSK-IMPACT, and METABRIC databases, in addition to our original data. [16] [17] [18] Bioinformatics data on HER2 alterations from these datasets are available through cBioportal for the Cancer Genomics website and are available to the public. detected. Because total-HER2 and phospho-HER2 in GCIY and NUGC4, which had been diagnosed as HER2-amplified from the copy number variation of HER2 examined by qPCR, were barely detectable in Western blot analyses, we analyzed these cell lines using FISH ( Figure 1D ). Based on the results, GCIY and NUGC4
were confirmed as HER2-amplified cell lines.
| Effects of afatinib and neratinib in HER2-amplified cell lines
We examined the effects of pan-HER inhibitors (afatinib and neratinib), anti-HER2 antibody (trastuzumab and pertuzumab), and EGFR inhibitor (gefitinib) in 12 gastric cancer cell lines (Table 1 , Figure S1 ).
We classified drug sensitivity into three groups based on the IC 50 values determined using an MTS assay. The IC 50 values <100 nmol/ L, 100-1000 nmol/L, and >1000 nmol/L were defined as highly sensitive, moderately sensitive, and insensitive to TKI, respectively. Four (GCIY, NCI-N87, NUGC4, and SNU-216) of the five HER2-amplified cell lines and NUGC3 were highly sensitive to both pan-HER inhibitors. The IC 50 value of afatinib and neratinib in these cells ranged from 0.7 to 39.5 nmol/L and from <0.15 to 63.8 nmol/L, respectively. NUGC4, the most afatinib-sensitive cell line, also showed EGFR amplification. Interestingly, the HER2-amplified MKN7 cell line was not highly sensitive to either of the pan-HER inhibitors, compared with other HER2-amplified cell lines; nevertheless, the activation of HER2 was revealed using Western blotting. In addition, MKN7 cells were also insensitive to lapatinib, which inhibits both EGFR and HER2 according to the CCLE database (IC 50 >8 lM). In most cell lines, the sensitivity of afatinib and neratinib showed the same tendency, except in the ECC10 and KATO-III cell lines, which were insensitive to afatinib and moderately sensitive to neratinib. All 12 cell lines were insensitive to trastuzumab and pertuzumab at a concentration of 1000 lg/mL.
Next, we evaluated the effect of afatinib and neratinib on the showed remarkable effects against NCI-N87 (P < 0.0001).
The expression level of p-HER2 in tumors obtained from mice xenografts after treatment was examined using IHC. In both NCI-N87 and NUGC4 cells treated with afatinib and neratinib, the F I G U R E 2 Influence of afatinib or neratinib on human epidermal growth factor receptor 2 (HER2) and the downsignal pathway in gastric cancer cell lines. Both afatinib and neratinib downregulate the phosphorylation (p-) of HER2 and epidermal growth factor receptor (EGFR) in tyrosine kinase inhibitor (TKI) highly and moderately sensitive cells. In addition to p-HER2, total-HER2 was also downregulated by pan-HER inhibitors in HER2-amplified cells. In NCI-N87, NUGC4, SNU-216, and MKN7 cells, p-ERK and p-AKT were downregulated in a dosedependent manner F I G U R E 3 Both afatinib and neratinib exerted an antitumor effect against HER2-amplified gastric cancer cells in vivo. A, In HER2-amplified NCI-N87 and NUGC4 xenografts, afatinib and neratinib inhibited cell growth in a nude mouse xenograft model. In particular, both drugs showed remarkable effects in NCI-N87 cells (P < 0.0001). The effects of afatinib and neratinib did not differ significantly in either cell line (NCI-N87, P = 0.6095; NUGC4, P = 0.2780). B, Photographs of the xenograft model taken on day 21. C, Representative images of immunohistochemical staining in tumors resected from xenograft model mice. In the pan-human epidermal growth factor receptor (HER) inhibitor-treated mice, the expression level of phosphorylated (p-)HER2 in tumors were not completely suppressed (positive weak p-HER2 expression), compared with the level in placebo-treated mice. Scale bar, 100 mm expression of p-HER2 was suppressed, compared with the expression level in tumors treated with the placebo (Figure 3C ). However, (Tables S1   and S2 ). Among these probes, 201163_s_at corresponded to IGFBP7, and we focused on IGFBP7 and IGF-1R to determine their abilities to predict and overcome resistance to pan-HER inhibitors in HER2-amplified gastric cancer.
Western blot analysis was used to determine the expression levels of IGFBP7 and IGF-1R in the TKI highly sensitive group and the moderately sensitive or insensitive group using the NCI-N87, NUGC4, and SNU-216 and the MKN7 and MKN74 cell lines, respectively ( Figure 4A ). The results showed that IGFBP7 was upregulated in the TKI highly sensitive group only, and the expression of total IGF-1R itself was less strongly correlated with TKI sensitivity. Subsequently, to determine whether IGF-1R had any impact on sensitivity to afatinib or neratinib, we undertook an MTT assay using the HER2-amplified MKN7 cell line, which had high levels of HER2 expression in both a gene expression assay and Western blot analysis ( Figure 4B ). To downregulate the activation of IGF-1R, we used PPP, an IGF-1R-targeting small molecule drug. Picropodophyllin inhibits phosphorylation of IGF-1R without interfering with insulin receptor activity and is reported to decrease IGF-1-stimulated phosphorylation of AKT. 22, 23 The cell proliferation ratios of the cells treated with afatinib, neratinib, or PPP compared with a control were 62.3%, 45.9%, and 54.1%, respectively. In contrast, the cell proliferation ratios when combinations of PPP plus afatinib or PPP plus neratinib were used were 26.9% and 12.9%, respectively, which were significantly lower than the single-use results (P < 0.0001). To reveal the synergistic effect of pan-HER inhibitors and PPP, we also undertook MTS assays and calculated the CI ( Figure 4C ). The effect of afatinib, neratinib, or PPP alone were compared to the effect of combination therapy (afatinib and PPP, or neratinib and PPP). The
F I G U R E 4
Relation between the effect of pan-human epidermal growth factor receptor (HER) inhibitors and insulin-like growth factorbinding protein 7 (IGFBP7) and insulin-like growth factor 1 receptor (IGF-1R) in gastric cancer cell lines. A, IGFBP7 was upregulated in tyrosine kinase inhibitor (TKI) highly sensitive (TKI-High) cells. Phosphorylated (p-)IGF-1R was upregulated in MKN74 cells, which were insensitive to both afatinib and neratinib. TKI-Insens, TKI insensitive; TKI-Mod, TKI moderately sensitive. B, In an MTT assay, a combined treatment co-targeting HER2 and IGF-1R produced a synergistic effect in MKN7 cells. In this assay, the concentrations of afatinib, neratinib, and picropodophyllin (PPP) were all 500 nmol/L, and the cells were exposed to the drugs for 3 days. MKN7 cells, cultured under the same conditions as in the MTT assay, were stained using crystal violet (photographs). C, Combination index (CI) and fraction affected (Fa) were calculated from the results of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. The calculated CI was <1 at all concentrations of combinations of afatinib and PPP, and neratinib and PPP), and the effects were shown to be synergistic combination therapy was effective in MKN7 cells, in which the expression of IGFBP7 was downregulated, and the effect was proved to be synergistic by the CI. In a Western blot analysis, PPP downregulated IGF-1R as well as the total and phospho-HER2 levels in the MKN7 cell line ( Figure S2 ).
| HER2 alteration in primary gastric cancers
To clarify possible candidates likely to benefit from pan-HER inhibitors, we analyzed 123 DNA samples obtained from primary gastric cancer patients. All the patients were Japanese, and 82 (66.7%) were men. The pathological stage and histology of the specimens are shown in Figure 5A ,B. We analyzed the HER2 copy number variation and mutations in exons 8 and 17-24. The HER2 copy number ranged from 1.27 to 192.04, and HER2 was amplified in 19 cases (15.4%) ( Figure 5C ). HER2 amplification was detected in both early and advanced cancer and in both diffuse and intestinal type (Table S3) .
Three mutations, S310F, D769_splice, and T862A, were detected in this study ( Figure 5D ); all of these mutations were evaluated as "disease causing" by MutationTaster2. Duplications of the HER2 mutation were not detected in this study, and HER2 amplification and mutation were mutually exclusive. S310F and T862A have already been reported as oncogenic mutations, 24 and D769_splice was detected as a novel mutation in HER2. Approximately half of the HER2-amplified tumors were HER2-positive when examined using IHC. The tumor with the S310F mutation was HER2-negative (1+) when examined using IHC ( Figure S3 ), although S310F is known to be an oncogenic change.
| DISCUSSION
The molecularly targeted treatment of gastric cancer has lagged behind that of lung cancer and breast cancer, considering the dramatic developments in genome analysis techniques and personalized medicine. Until now, the effect of pan-HER inhibitors, afatinib and neratinib, has been reported in some articles, using a limited number of cell lines. 25 In the present study, we determined the molecular reportedly plays a role as a tumor suppressor gene in breast cancer, colorectal cancer, and hepatocellular carcinoma. [28] [29] [30] The association of HER family protein and IGF-1R has also been well-documented, 31, 32 and low expression of IGFBP7 is correlated with poor prognosis in high-grade serous ovarian carcinoma. 33 The activation of IGF-1R might influence the sensitivity of pan-HER inhibitors indirectly, as IGF-1R reportedly forms a heterodimer with EGFR. 32 The effect of co-targeting HER2 and IGF-1R therapy has already been reported in HER2 non-overexpressing breast cancer. 34 Based on these facts, we decided to undertake experiments to overcome the resistance against afatinib or neratinib in HER2-amplified, but not highly sensitive, cells using a combination therapy consisting of a pan-HER inhibitor and an IGF-1R inhibitor. As a result, the combination of afatinib or neratinib with PPP produced a sufficient effect.
Although the detailed mechanisms remain unclear, PPP downregu- Although gastric cancer is still a leading cause of cancer deaths in East Asia, 39 the frequency and types of HER2 alterations in gastric cancer, especially mutations, remain unknown. In the present study, we analyzed 123 DNA samples extracted from primary gastric cancers in Japanese patients and compared the results with the TCGA and MSK-IMPACT datasets (Table S4) . 40 In terms of HER2 alterations other than amplification, S310F (exon 8) is the most frequent oncogenic mutation of HER2 in gastric cancer, according to the TCGA dataset, and some mutations in the transmembrane domain or kinase domain have also been reported as oncogenic HER2 alterations. 14 Thus, we undertook the direct sequencing of exons 8 and 17-24, which contain the transmembrane domain and the kinase domain of HER2. Only information for esophagogastric cancer was obtained from the MKS-IMPACT dataset and compared with our data, and a certain number of HER2 alterations in esophageal cancer were also included. The frequencies of HER2 amplification in the TCGA and MSK-IMPACT databases and in our study were 14.0%, 22.6%, and 15.4%, respectively, and the frequencies of mutation were 4.8%, 3.8%, and 2.4%, respectively. Regarding HER2 mutations, we cannot conclude whether the frequency of gastric cancer in our series was higher or lower than those in the TCGA or MSK-IMPACT datasets because we only analyzed nine of the 27 exons of HER2. Among the three mutations identified in this study, D769_splice might have a limited significance because HER2 was hardly detected using IHC, although this mutation was diagnosed as an oncogenic change by MutationTaster2.
Even though the relation between oncogenic HER2 mutations and drug sensitivity to afatinib or neratinib in gastric cancer needs further investigation, the antitumor effects of these drugs against HER2-mutated lung cancer and breast cancer have already been reported. 4, 24 The amplification and mutation of HER2 were mutually exclusive, not only in our study examining gastric cancer, but also in studies examining lung or breast cancer according to the TCGA, MSK-IMPACT, and METABRIC databases. 18 Considering the exclusiveness of HER2 alterations, patients suffering from HER2-mutated gastric cancer might not be currently receiving anti-HER2 drugs, and pan-HER inhibitors could contribute to the treatment of these patients.
In conclusion, pan-HER inhibitors exert a strong antitumor effect against HER2-amplified gastric cancer cells and could be a promising treatment option for HER2-positive gastric cancer patients. Our findings also suggest that IGFBP7 expression might be a useful biomarker for the selection of patients who are likely to be sensitive to pan-HER inhibitors.
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